A research team at the University of Würzburg has gained new insights into the development of kidney tumors in young children. These enable a better risk assessment and could form the basis for ...

A research team at the University of Würzburg has gained new insights into the development of kidney tumors in young children ...

GPS, a WT1-targeting cancer vaccine, showed an 80% T-cell response rate, with no new safety concerns reported. The REGAL trial aims to establish GPS as a transformative treatment for AML, with final ...

WT1 factor is a promising biomarker for MRD monitoring, offering widespread applicability in AML cases and aiding pre-transplant clinical decisions. A study demonstrated that pre-transplant ...

Data showed substantial evidence of selective expansion of WT1-specific T cells, with anti-tumor activity and a favorable tolerability profile with no dose limiting toxicities (DLTs) observed.

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial ...

Real-world use of anti-EGFR therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

They then perform Wt1- and MafB-ChIP-Seq analysis to identify respective direct targets of those transcription factors. Subsequently, they employ an inducible MafB knockout model and show that ...

By employing constitutive and inducible podocyte specific knockout animals, we show that MAFB is essential for the activation of the podocyte specific gene program, by opening chromatin and permitting ...